Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (DE:XE7C)
:XE7C
XE7C Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.82 - €5.59
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€218.71M
Enterprise Value€69.15M
Total Cash (Recent Filing)$21.66M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
May 01, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding66,524,290
10 Day Avg. Volume51
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)348.69
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit101.24
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
€13.09Price Target Upside272.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Cardiff Oncology News
PremiumCompany Announcements
Cardiff Oncology’s Earnings Call: Optimism Amid Challenges
PremiumCompany Announcements
Cardiff Oncology Highlights Progress in Cancer Trials
---
Bulls Say, Bears Say
Bulls Say
Efficacy Of OnvansertibOnvansertib 30mg combined with standard-of-care demonstrated a 64% objective response rate, showing highly promising results in the CRDF-004 trial.
Market PotentialThe KRAS+ colorectal cancer market is underserved, and successful results with onvansertib could drive a paradigm shift in treatment and make Cardiff Oncology an attractive acquisition target.
Bears Say
Clinical Trial RisksRisks include negative or poorer-than-anticipated clinical results for onvansertib in the ongoing CRDF-004 trial.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.57% Insiders
4.86% Mutual Funds
22.23% Other Institutional Investors
62.88% Public Companies and
Individual Investors
XE7C FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was €1.82 and its highest was €5.59 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is €218.71M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is May 01, 2025 which is in 49 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Feb 27, 2025. The company reported -€0.202 earnings per share for the quarter, beating the consensus estimate of -€0.226 by €0.024.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.18.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 66,524,290 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -€0.202 in its last earnings report, beating expectations of -€0.226. Following the earnings report the stock price went down -5.19%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in DE:XE7C
---
Cardiff Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.09 (272.84% Upside)
€13.09 (272.84% Upside)
Blogger Sentiment
Bullish
DE:XE7C Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.36%
12-Months-Change
Fundamentals
Return on Equity
-59.51%
Trailing 12-Months
Asset Growth
19.05%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
---
XE7C Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong initial clinical data, successful capital raising efforts, and a solid financial position. However, some dependency on future FDA meetings and the early stage of PFS data might pose challenges. Overall, the sentiment is optimistic with clear progress, yet some uncertainties remain.Read More>---
XE7C Stock 12 Month Forecast
Average Price Target
€13.09
▲(272.84% Upside)
Technical Analysis
Exelixis
―
Gilead Sciences
―
Karyopharm Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering XE7C
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+24.91%
reiterated a buy rating 14 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +24.91% per trade.
---